T. Rowe Price Associates’s Endocyte, Inc. Common Stock ECYT Stock Holding History

T. Rowe Price Associates’s Portfolio ECYT Stock Details ECYT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q4	–	Sell	-3,261,891	Closed	-$57.9M	–	2620
2018 Q3	$57.9M	Buy	3,261,891 +642,082	+25%	+$11M	0.01%	859
2018 Q2	$36.2M	Sell	2,619,809 -489,991	-16%	-$5.82M	0.01%	1007
2018 Q1	$28.3M	Buy	+3,109,800	New	+$17.2M	﹤0.01%	1065
2014 Q1	–	Sell	-300,500	Closed	-$3.21M	–	2529
2013 Q4	$3.21M	Sell	300,500 -1,400	-0.5%	-$15.5K	﹤0.01%	1478
2013 Q3	$4.02M	Buy	301,900 +1,100	+0.4%	+$17.4K	﹤0.01%	1457
2013 Q2	$3.95M	Buy	+300,800	New	+$4.06M	﹤0.01%	1445

Other funds holding ECYT

OTC

Opera Trading Capital Paris, France $419M AUM 0.58% 1-Year Est. Return

Claro Advisors Boston, Massachusetts $953M AUM 24.79% 1-Year Est. Return

T. Rowe Price Associates's ECYT Position: Q4 2018 in Review

T. Rowe Price Associates sold out of Endocyte, Inc. Common Stock (ECYT) in Q4 2018, closing a stake of 3,261,891 shares — an estimated $57.9M sold.

T. Rowe Price Associates first reported a position in ECYT in Q2 2013 and held it in 6 quarters. The position peaked at $57.9M in Q3 2018. 2 funds tracked by Wall St. Rank hold ECYT as of Q4 2018.

T. Rowe Price Associates reported no remaining Endocyte, Inc. Common Stock position as of Q4 2018 after selling out during the quarter.
T. Rowe Price Associates sold 3,261,891 Endocyte, Inc. Common Stock shares in Q4 2018, an estimated $57.9M.
T. Rowe Price Associates first reported a position in Endocyte, Inc. Common Stock in Q2 2013 and held it in 6 quarters.
T. Rowe Price Associates's Endocyte, Inc. Common Stock position peaked at $57.9M in Q3 2018.
2 funds tracked by Wall St. Rank held Endocyte, Inc. Common Stock as of Q4 2018.

Based on T. Rowe Price Associates's 13F filing for Q4 2018, filed 14 Feb 2019.